BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1968 related articles for article (PubMed ID: 15809451)

  • 1. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
    Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma.
    Yun JP; Suh C; Lee E; Chang JW; Yang WS; Park JS; Park SK
    J Korean Med Sci; 2006 Aug; 21(4):639-44. PubMed ID: 16891806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
    Tichý M; Maisnar V; Palicka V; Friedecký B; Vávrová J; Novotná H; Cermáková Z; Dastych M; Cechák P; Vogtová D; Jarolímková E; Benáková H; Hachová L; Bezdícková D; Kouril F; Zábranská EA; Zenková J; Slabý P; Scudla V; Gregora E; Spicka I; Straub J; Schützova M; Hájek R
    Neoplasma; 2006; 53(6):492-4. PubMed ID: 17167717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of criteria in staging in multiple myeloma.
    Pennec Y; Mottier D; Youinou P; Asselain B; Miossec P; Le Goff P; Le Prise PY; Le Menn G
    Haematologia (Budap); 1982; 15(2):221-6. PubMed ID: 7160667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma in elderly patients: prognostic factors and outcome.
    Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
    Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Classification, staging and prognostic indices for multiple myeloma].
    Hotta T
    Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.